Copyright Reports & Markets. All rights reserved.

Global Nintedanib Generics Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Nintedanib Generics Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 100mg per Unit
    • 1.3.3 150mg per Unit
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Nintedanib Generics Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Non-small Cell Lung Cancer
    • 1.4.3 Idiopathic Pulmonary Fibrosis
    • 1.4.4 Other
  • 1.5 Global Nintedanib Generics Market Size & Forecast
    • 1.5.1 Global Nintedanib Generics Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Nintedanib Generics Sales Quantity (2021-2032)
    • 1.5.3 Global Nintedanib Generics Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Cipla
    • 2.1.1 Cipla Details
    • 2.1.2 Cipla Major Business
    • 2.1.3 Cipla Nintedanib Generics Product and Services
    • 2.1.4 Cipla Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Cipla Recent Developments/Updates
  • 2.2 Beacon Pharma
    • 2.2.1 Beacon Pharma Details
    • 2.2.2 Beacon Pharma Major Business
    • 2.2.3 Beacon Pharma Nintedanib Generics Product and Services
    • 2.2.4 Beacon Pharma Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Beacon Pharma Recent Developments/Updates
  • 2.3 Eskayef Pharmaceuticals
    • 2.3.1 Eskayef Pharmaceuticals Details
    • 2.3.2 Eskayef Pharmaceuticals Major Business
    • 2.3.3 Eskayef Pharmaceuticals Nintedanib Generics Product and Services
    • 2.3.4 Eskayef Pharmaceuticals Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Eskayef Pharmaceuticals Recent Developments/Updates
  • 2.4 Glenmark
    • 2.4.1 Glenmark Details
    • 2.4.2 Glenmark Major Business
    • 2.4.3 Glenmark Nintedanib Generics Product and Services
    • 2.4.4 Glenmark Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Glenmark Recent Developments/Updates
  • 2.5 CSPC Pharmaceutical Group
    • 2.5.1 CSPC Pharmaceutical Group Details
    • 2.5.2 CSPC Pharmaceutical Group Major Business
    • 2.5.3 CSPC Pharmaceutical Group Nintedanib Generics Product and Services
    • 2.5.4 CSPC Pharmaceutical Group Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 CSPC Pharmaceutical Group Recent Developments/Updates
  • 2.6 Qilu Pharmaceutical
    • 2.6.1 Qilu Pharmaceutical Details
    • 2.6.2 Qilu Pharmaceutical Major Business
    • 2.6.3 Qilu Pharmaceutical Nintedanib Generics Product and Services
    • 2.6.4 Qilu Pharmaceutical Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.7 PuraCap
    • 2.7.1 PuraCap Details
    • 2.7.2 PuraCap Major Business
    • 2.7.3 PuraCap Nintedanib Generics Product and Services
    • 2.7.4 PuraCap Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 PuraCap Recent Developments/Updates
  • 2.8 Jiangsu Wangao Pharmaceutical
    • 2.8.1 Jiangsu Wangao Pharmaceutical Details
    • 2.8.2 Jiangsu Wangao Pharmaceutical Major Business
    • 2.8.3 Jiangsu Wangao Pharmaceutical Nintedanib Generics Product and Services
    • 2.8.4 Jiangsu Wangao Pharmaceutical Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Jiangsu Wangao Pharmaceutical Recent Developments/Updates
  • 2.9 Kelun Pharmaceutical
    • 2.9.1 Kelun Pharmaceutical Details
    • 2.9.2 Kelun Pharmaceutical Major Business
    • 2.9.3 Kelun Pharmaceutical Nintedanib Generics Product and Services
    • 2.9.4 Kelun Pharmaceutical Nintedanib Generics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.9.5 Kelun Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Nintedanib Generics by Manufacturer

  • 3.1 Global Nintedanib Generics Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Nintedanib Generics Revenue by Manufacturer (2021-2026)
  • 3.3 Global Nintedanib Generics Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Nintedanib Generics by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Nintedanib Generics Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Nintedanib Generics Manufacturer Market Share in 2025
  • 3.5 Nintedanib Generics Market: Overall Company Footprint Analysis
    • 3.5.1 Nintedanib Generics Market: Region Footprint
    • 3.5.2 Nintedanib Generics Market: Company Product Type Footprint
    • 3.5.3 Nintedanib Generics Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Nintedanib Generics Market Size by Region
    • 4.1.1 Global Nintedanib Generics Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Nintedanib Generics Consumption Value by Region (2021-2032)
    • 4.1.3 Global Nintedanib Generics Average Price by Region (2021-2032)
  • 4.2 North America Nintedanib Generics Consumption Value (2021-2032)
  • 4.3 Europe Nintedanib Generics Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Nintedanib Generics Consumption Value (2021-2032)
  • 4.5 South America Nintedanib Generics Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Nintedanib Generics Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Nintedanib Generics Sales Quantity by Type (2021-2032)
  • 5.2 Global Nintedanib Generics Consumption Value by Type (2021-2032)
  • 5.3 Global Nintedanib Generics Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Nintedanib Generics Sales Quantity by Application (2021-2032)
  • 6.2 Global Nintedanib Generics Consumption Value by Application (2021-2032)
  • 6.3 Global Nintedanib Generics Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Nintedanib Generics Sales Quantity by Type (2021-2032)
  • 7.2 North America Nintedanib Generics Sales Quantity by Application (2021-2032)
  • 7.3 North America Nintedanib Generics Market Size by Country
    • 7.3.1 North America Nintedanib Generics Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Nintedanib Generics Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Nintedanib Generics Sales Quantity by Type (2021-2032)
  • 8.2 Europe Nintedanib Generics Sales Quantity by Application (2021-2032)
  • 8.3 Europe Nintedanib Generics Market Size by Country
    • 8.3.1 Europe Nintedanib Generics Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Nintedanib Generics Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Nintedanib Generics Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Nintedanib Generics Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Nintedanib Generics Market Size by Region
    • 9.3.1 Asia-Pacific Nintedanib Generics Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Nintedanib Generics Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Nintedanib Generics Sales Quantity by Type (2021-2032)
  • 10.2 South America Nintedanib Generics Sales Quantity by Application (2021-2032)
  • 10.3 South America Nintedanib Generics Market Size by Country
    • 10.3.1 South America Nintedanib Generics Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Nintedanib Generics Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Nintedanib Generics Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Nintedanib Generics Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Nintedanib Generics Market Size by Country
    • 11.3.1 Middle East & Africa Nintedanib Generics Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Nintedanib Generics Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Nintedanib Generics Market Drivers
  • 12.2 Nintedanib Generics Market Restraints
  • 12.3 Nintedanib Generics Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Nintedanib Generics and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Nintedanib Generics
  • 13.3 Nintedanib Generics Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Nintedanib Generics Typical Distributors
  • 14.3 Nintedanib Generics Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Nintedanib Generics market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
    Nintedanib generics are alternative versions of the branded drug Nintedanib,usually available in capsule form,and is used for treating conditions like non-small cell lung cancer(NSCLC),idiopathic pulmonary fibrosis(IPF),and certain other cancers.These generics contain the same active ingredient and have the same therapeutic effects as the brand-name drug,working as a multi-kinase inhibitor.
    This report is a detailed and comprehensive analysis for global Nintedanib Generics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Nintedanib Generics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Nintedanib Generics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Nintedanib Generics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
    Global Nintedanib Generics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Nintedanib Generics
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Nintedanib Generics market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Cipla, Beacon Pharma, Eskayef Pharmaceuticals, Glenmark, CSPC Pharmaceutical Group, Qilu Pharmaceutical, PuraCap, Jiangsu Wangao Pharmaceutical, Kelun Pharmaceutical, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market Segmentation
    Nintedanib Generics market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    100mg per Unit
    150mg per Unit
    Market segment by Application
    Non-small Cell Lung Cancer
    Idiopathic Pulmonary Fibrosis
    Other
    Major players covered
    Cipla
    Beacon Pharma
    Eskayef Pharmaceuticals
    Glenmark
    CSPC Pharmaceutical Group
    Qilu Pharmaceutical
    PuraCap
    Jiangsu Wangao Pharmaceutical
    Kelun Pharmaceutical
    Market segment by region, regional analysis covers
    North America (United States, Canada, and Mexico)
    Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
    Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
    South America (Brazil, Argentina, Colombia, and Rest of South America)
    Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 15 chapters:
    Chapter 1, to describe Nintedanib Generics product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top manufacturers of Nintedanib Generics, with price, sales quantity, revenue, and global market share of Nintedanib Generics from 2021 to 2026.
    Chapter 3, the Nintedanib Generics competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
    Chapter 4, the Nintedanib Generics breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
    Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Nintedanib Generics market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
    Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
    Chapter 13, the key raw materials and key suppliers, and industry chain of Nintedanib Generics.
    Chapter 14 and 15, to describe Nintedanib Generics sales channel, distributors, customers, research findings and conclusion.

    Buy now